1Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer[J]. Cancer J, 2008, 14(5):288-301.
2Hupertan V, Roupret M, Poisson JF, et al. Low predictive accuracy of Kattan's postoperative nomogram for renal cell carcinoma recurrence in a population of French patients[J]. Cancer, 2006, 107(11):2604-2608.
3Zisman A, Pantuck A J, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system[J]. J Clin Oncol, 2001, 19(6): 1649-1657.
4Patard JJ, Kim HL, Lam JS, et al. Use of the university of california los angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study[J]. J Clin Oncol, 2004, 22 (16):3316-3322.
5Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma [J]. J Clin Oncol, 2002, 20(1):289-296.
6Mekhail TM, Abou-Jawde RM, Bournerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma[J]. J Clin Oncol, 2005, 23(4):832-841.
7Bamias A, Karadimou A, Lampaki S, et al. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib, comparison with the memorial sloan-kettering prognostic factors model[J]. BMC Cancer, 2009, 10(1):45.
9Ficarra V, Martignoni G, Lohse C, et al. External validation of the mayo clinic stage, size, grade and necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma[J]. J Urol, 2006, 175(4): 1235-1239.
10Fujii Y, Saito K, Iimura Y, et al. External validation of the mayo clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma[J]. J Urol, 2008, 180(180): 1290-1295.
2Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Mcd, 2007, 356 : 125- 134.
3Motzer RJ, Hustson TE, Tomezak P, et al. Sunitinib versus in- terferon alfa in metastatic renal-cell carcinoma. N Engl J Ned, 2007, 356: 115-124.
4McDermott DF, Regan MM, Clark JI, et al. Randomized phase IIl trial of high-dose interleukin-2 versus subcutaneous interleu- kin-2 and interferon in patients with metastatic renal cell carcino- ma. J Clin Oncol, 2005, 23: 133-141.
5Negrier S, Perol D, Ravaud A, et al. Medroxy-progesterone, in- terferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prog- nosis: results of a randomized controlled trial. Cancer, 2007, 110 : 2468-2477.
6Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of thephase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol, 2009, 27: 3312-3318.
7Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a co- operative group report of 1463 patients. Eur Urol, 2010, 57: 317-325.
8Zhang H, Dong B, Lu J, et al. Efficacy of sorafenib on metasta- tic renal cell carcinoma in Asian patients: results from a multi- center study. BMC Cancer, 2009, 9: 249-256.
9Yuasa T, Tsuchiya N, Urakami S, et al. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cellcancer treated with sunitlnib. BJU Int, 2011, 109 : 1349-1354.
10Kim HS, Hong MH, Kim K, et al. Sunitinib hlr Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology, 2011 , 80 : 395-405.
